AI Mental Health & Emotional Companionship 2026: Clinical Evidence, Regulatory Turn, and the US-China Landscape

Companion apps are the traffic engine of this space. Character.AI holds roughly 20 million MAU per third-party estimates (down from a mid-2024 peak of ~28 million), with daily usage of roughly 75 minutes to 2 hours depending on methodology. Replika (Luka) claims 40 million+ cumulative users, but Harvard Business School researchers estimate only ~2.5 million MAU—the gap between cumulative downloads and retained actives is the single biggest data trap in this category. On revenue, Appfigures estimates companion apps earned ~USD 120 million globally in 2025 (+64% YoY) on 220 million cumulative downloads; romance/adult-flavored companion apps earned ~USD 162.8 million in H1 2026, with the top 10% of apps capturing ~89% of revenue. Penetration data matters more: Common Sense Media (July 2025, n=1,060) found 72% of US teens have tried AI companions and 52% use them at least a few times a month; KFF (March 2026) found one in six US adults sought mental-health advice from AI in the past year (28% among ages 18-29). Demand is real—but much of it flows to general-purpose chatbots never designed for mental-health contexts, which is precisely where the regulation and litigation stories begin.

In 2025-2026 the therapy segment received both its best evidence and its sharpest rebuttal. Positive: Dartmouth's Therabot delivered the first RCT of a generative-AI therapy chatbot in NEJM AI (March 2025, n=106, covering major depression, generalized anxiety, and eating-disorder risk), with a 51% mean reduction in depression and 31% in anxiety symptoms over four weeks—improvements the authors called comparable to reported outpatient therapy levels, though the small, short trial awaits larger independent replication. The UK NHS offers a different evidence class: Limbic's AI referral tool is used by ~40% of NHS Talking Therapies services (Nature Medicine 2024: 129,400 patients across 28 sites, +15% referrals vs. +6% in controls); Wysa has served 117,000+ patients across 31 NHS services since 2022, with NICE currently assessing such tools. Negative: a June 2025 Stanford study found tested "therapy" bots showed stigmatizing tendencies toward schizophrenia and alcohol dependence and sometimes responded inappropriately—even dangerously—to suicidal ideation and delusions, with larger, newer models no safer. The APA's November 2025 health advisory states plainly that general-purpose chatbots and wellness apps were not designed to deliver mental health care and should not replace professional treatment. The honest industry conclusion: early evidence supports AI-assisted triage and mild-to-moderate support—not AI-as-therapist.

From H2 2025 through 2026, the rules of this market took shape. Federally, the FDA convened its first Digital Health Advisory Committee meeting on generative-AI mental health devices on November 6, 2025: the agency has authorized 1,200+ AI medical devices but zero generative-AI mental health therapeutics, and the committee flagged hallucination, sycophancy, and model drift, with the FDA signaling enforcement priority on higher-harm use cases. The FTC issued 6(b) compulsory orders in September 2025 to seven companies including Alphabet, Meta, Instagram, OpenAI, Snap, xAI, and Character Technologies. At the state level, Illinois's WOPR Act (August 2025, fines up to USD 10,000 per violation) and Nevada's AB 406 pioneered outright bans; as of July 2026 four states ban AI-delivered therapy, while California SB 243 (effective January 1, 2026) imposes disclosure, crisis-protocol, and minor-protection duties on companion bots with a private right of action. In litigation, a Florida federal court largely denied dismissal in Garcia in May 2025, preliminarily holding AI outputs are not automatically First Amendment-protected; on January 7, 2026, Character.AI and Google settled five teen-harm cases (terms undisclosed), while Raine v. OpenAI remains pending. In the UK, Slingshot AI withdrew its therapy chatbot Ash in January 2026 over medical-device concerns—the boundary fight between "regulate as device" and "regulate as consumer product" is now the global storyline.

China delivered 2026's most systematic regulatory answer. The Interim Measures on Anthropomorphic AI Interaction Services (Order No. 21), jointly issued by the CAC, NDRC, MIIT, Ministry of Public Security, and SAMR, took effect July 15, 2026, and is widely viewed as the world's first dedicated regulation of anthropomorphic AI emotional interaction: virtual companion/kinship services are banned for all minors; guardian consent is required for users under 14; content glorifying self-harm or suicide is prohibited; services may not "excessively cater to users or induce emotional dependence or addiction"; providers must detect extreme emotional states and intervene; and health-related use cases must additionally comply with sector regulators. On market size, LeadLeo Research forecasts China's AI emotional companionship market growing from ~RMB 3.87 billion (2025) to ~RMB 59.5 billion (2028)—a projection with wide error bars that warrants caution. Operating data suggest growth has already downshifted: per media citing third-party trackers, Xingye's monthly downloads fell from 4.86 million to 0.93 million over January-May 2025, Maoxiang's DAU slipped from ~590k to ~490k, and from April 2026 several apps including Zhumengdao and EchoMe were publicly flagged for sexualized content and inadequate minor protections. On the counseling side, platforms like Yidianling run a hybrid "AI-assisted assessment + human counselor" model—public reports cite 43 million+ registered users and 30,000+ onboarded counselors, plus a 2025 AI psychological assessment standard released with Qingzhou Technology. Under the new rules, "AI for front-end assessment and companionship, humans for counseling and treatment" may become China's dominant compliant structure.